What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Cancer
- Gene
Melanoma, Internal medicine, Oncology, Dabrafenib and Surgery are her primary areas of study.
Georgina V. Long has included themes like Cancer, Immunotherapy and Clinical trial in her Melanoma study.
Her Ipilimumab, Pembrolizumab, Hazard ratio, Combination therapy and Phases of clinical research investigations are all subjects of Internal medicine research.
Her research in Oncology intersects with topics in V600E, Disease, Genotype, Biomarker and Survival analysis.
Her Dabrafenib research incorporates themes from Keratoacanthoma, Dermatology, Biopsy, Carcinoma and Trametinib.
The Surgery study combines topics in areas such as Gastroenterology and Adverse effect.
Her most cited work include:
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4968 citations)
- Nivolumab in previously untreated melanoma without BRAF mutation. (3560 citations)
- Pembrolizumab versus Ipilimumab in Advanced Melanoma (3520 citations)
What are the main themes of her work throughout her whole career to date?
Georgina V. Long mainly focuses on Melanoma, Internal medicine, Oncology, Cancer research and Ipilimumab.
Her Melanoma research integrates issues from Cancer, Targeted therapy, Immunotherapy, Clinical trial and Surgery.
In Internal medicine, Georgina V. Long works on issues like Trametinib, which are connected to MEK inhibitor.
Her research integrates issues of Metastatic melanoma, Advanced melanoma, Adverse effect and Phases of clinical research in her study of Oncology.
Her Cancer research study combines topics from a wide range of disciplines, such as Mutation, Mutant, Immune system, Neuroblastoma RAS viral oncogene homolog and MAPK/ERK pathway.
The concepts of her Ipilimumab study are interwoven with issues in Adjuvant therapy, Discontinuation, Toxicity and Cohort.
She most often published in these fields:
- Melanoma (80.58%)
- Internal medicine (74.64%)
- Oncology (54.85%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (74.64%)
- Melanoma (80.58%)
- Oncology (54.85%)
In recent papers she was focusing on the following fields of study:
Georgina V. Long focuses on Internal medicine, Melanoma, Oncology, Ipilimumab and Nivolumab.
As part of her studies on Internal medicine, Georgina V. Long often connects relevant areas like Gastroenterology.
Her study with Melanoma involves better knowledge in Cancer research.
The various areas that Georgina V. Long examines in her Oncology study include Trametinib and Phases of clinical research.
The Ipilimumab study combines topics in areas such as Anti pd 1, Colitis and Combination therapy.
Her work deals with themes such as Health related quality of life and Lymph node, which intersect with Nivolumab.
Between 2019 and 2021, her most popular works were:
- Pan-cancer analysis of whole genomes (751 citations)
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial (113 citations)
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. (99 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Her primary scientific interests are in Internal medicine, Melanoma, Oncology, Ipilimumab and Pembrolizumab.
Her Internal medicine study combines topics in areas such as Gastroenterology and Trametinib.
Her work carried out in the field of Melanoma brings together such families of science as Stage and Immunotherapy.
Her Oncology research includes themes of Nivolumab, MEK inhibitor, Clinical endpoint and Cohort.
As a part of the same scientific study, Georgina V. Long usually deals with the Nivolumab, concentrating on Progression-free survival and frequently concerns with Retrospective cohort study.
Her studies deal with areas such as Response Evaluation Criteria in Solid Tumors, Placebo, Advanced melanoma and Hazard ratio as well as Pembrolizumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
